Pancreatic Cancer

Gene therapy may enhance effectiveness of chemotherapeutic agents

Published in Gene Therapy Weekly, September 19th, 2002

GenVec, Inc., (GNVC), a biopharmaceutical company developing gene-based medicines, announced that a scientific paper, "Transcriptional Control of Viral Gene Therapy by Cisplatin" by Weichselbaum et al, indicates that GenVec's TNFerade gene therapy may be useful in enhancing the effectiveness of chemotherapy for patients with cancer.

The study was published in the prestigious Journal of Clinical Investigation.

TNFerade, GenVec's lead oncology product candidate, is in phase IIb clinical trials in patients with pancreatic cancer. TNFerade is being tested in combination with standard radiation therapy and the chemotherapeutic drug, fluorouracil,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-09-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry